The Effectiveness of Mindfulness Based on Stress Managment on Death Anxiety, Disaster of Imagination, Acceptance and Severity of Pain in Prostat Cancer Patients

Haghdoost, Mohammadreza; Sarajkhorrami, Naser; Makvandi, Behnam

doi:10.52547/sjimu.29.6.48

Cited by 1 publication

(1 citation statement)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Prostate cancer (PC) is by far the most widely recognized malignancy in males [ 1 ] and the second most common cancer mortality [ 2 ], with new cases expected to emerge globally and a high death rate [ 3 ]. Due to PC's great clinical and economic significance [ 4 ], extensive research has resulted in the fast growth of metastatic therapeutic options [ 5 , 6 ].…”

Section: Introductionmentioning

confidence: 99%

In Vivo Growth Inhibition of Human Caucasian Prostate Adenocarcinoma in Nude Mice Induced by Amygdalin with Metabolic Enzyme Combinations

Alwan

Afshari

2022

BioMed Research International

View full text Add to dashboard Cite

Cancer of the prostate is an indicated type that is often recorded as a kind of cancer in men and the second critical cause of mortality through cancer cases. Many pharmacological investigations have shown that numerous herbal substances possess anticancer action. Amygdalin (AMD) has antitumour capabilities and works as an antioxidant, antibacterial, anti-inflammatory, and immune-regulating characteristics. The anticancer effects of amygdalin and its metabolizing enzymes, rhodanese (RHD) and betaglucosidase (BGD), were examined in vivo, as well as their antitumour processes. Novel, effective combination agents are necessary to increase existing cancer treatment rates. This research was aimed at determining the anticarcinogenic impact of amygdalin (AMD) in vivo. This research was aimed at determining the RHD and BGD on the anticarcinogenic impact of AMD in vivo. Subcutaneously, PC3 prostate cancer cell lines were implanted into nude mice. Mice were treated every day with 0.5 ml of 50 mg/ml (AMD), AMD+ (RHD 0.1 mg/ml), AMD+(BGD 0.1 mg/ml), and doxorubicin (DOX 50 mg/ml). Mice were normalized for negative control with untreated mice. In in vivo, morphopathological alterations in the tumour tissue were analyzed by histopathological staining methods. After 35 days of therapy, tumour growth and size inhibition were evident, indicating a function for the metabolic enzymes BGD and RHD in regulating AMD’s anticancer effect in vivo. We concluded the critical role of metabolic enzymes BGD and RHD in elevating the antigrowth of PC3 cancer cell lines in Balb/c nude mice treated with AMD.

show abstract